A phase I/II clinical study of VE800 in combination with Opdivo (nivolumab) in advanced or metastatic cancers
Phase of Trial: Phase I/II
Latest Information Update: 23 Sep 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; VE 800 (Primary)
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- 23 Sep 2019 According to a Vedanta Biosciences media release, the funding from recent series C-2 financing ($16.6 million) will support this trial.
- 19 Nov 2018 New trial record
- 06 Nov 2018 Acording to a Vedanta Biosciences media release, the company expects to initiate a clinical study of VE800 in mid-2019.